US 2025/0049916 A1 · USE OF CCL13

Abstract

The chemotactic binding ability of CCL13 and an immune cell surface receptor such as DC cells is used to transport different antigenic proteins to the surface of the DC cells, the efficiency of phagocytosis, processing, and presentation of various antigenic proteins by the DC cells is improved, and the effect of preventing and treating related diseases of the antigenic proteins is enhanced. A T2 sequence is further added in an antigen, such that the immune effect can be enhanced.

Claims12

Dependent claims

A method for improving antigen presentation effect, comprising administering to a subject in need thereof at least one of I)-VI);

I) a T2 fragment with an amino acid sequence set forth in SEQ ID NO:
4;
II) chemokine CCL13;
III) a fragment being more than 80% homologous with and functionally identical or similar to I) or II);
IV) a nucleic acid molecule encoding I) or II);
V) a nucleic acid molecule that is derived from the nucleotide sequence of the nucleic acid molecule in IV) by deletion, addition or substitution of one or more nucleotides and encode a protein functionally identical or similar to the nucleic acid molecule in IV);
VI) a nucleic acid molecule fully or partially complementary to V).

4 more elements

Dependencies are inferred from the claim text.

Facts

Application

18/719,415Filed 6 Jun 2022

Priority

CN 202210076816.724 Jan 2022

Published

13 Feb 2025

Term ends

Not estimatedThe source records don’t support an estimate.

Classification30 codes

A61K 39/39
Medicinal preparations containing antigens or antibodies: characterised by the immunostimulating additives, e.g. chemical adjuvants
A61K 39/0011
Vertebrate antigens: cancer antigens
A61K 39/001142
Cytokines: chemokines
A61K 39/12
Medicinal preparations containing antigens or antibodies: viral antigens

Use of ccl13

Life of this patent

Use of ccl13

Life of this patent

Abstract

Claims12